Recent Updates
Recently added Catalysts
OKYO Positive Sentiment

OKYO Pharma Announces Purchase of Shares by Chief Development Officer and Director

Wednesday, July 22, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: OKYO Pharma Limited announced that Gary S. Jacob, its Chief Development Officer and Director, has purchased an additional 3,500 shares at $1.40 each, increasing his total holdings to 112,420 shares. The company is preparing to launch a global Phase 3 clinical trial for urcosimod, aimed at treating neuropathic corneal pain, with plans to enroll around 111 patients.
Price reaction · baseline $1.45 (2026-07-22T13:46:00.000Z) · hit during market hours · clean, no other OKYO news in the window
day 0 close · peak
+4.8%

Market Sentiment Analysis

POSITIVE FACTORS

  • Chief Development Officer increased his shareholding, indicating confidence.
  • OKYO Pharma is advancing towards a Phase 3 clinical trial.
  • The company is focused on developing innovative therapies for eye diseases.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+14%
120-day peak, hindsight
Typical move
5.1%
average across 4 past catalysts
Lead asset
Urcosimod is a preservative-free product; supplied in unit dose ampoules; administered QID for 12-weeks
Phase 3 · Neuropathic Corneal Pain

Full Press Release Details

LONDON and NEW YORK, July 22, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq:OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain (NCP) and anterior segment eye diseases, today announced that Gary S. Jacob, PhD, Chief Development Officer and Director of OKYO Pharma has increased his holdings with the purchase of 3,500 of the Company’s ordinary shares on NASDAQ at $1.40 per share, bringing his total holding to 112,420 ordinary shares.

About OKYOPharma

OKYO Pharma Limited (Nasdaq: OKYO) is a clinical-stage biopharmaceutical company developing innovative therapies for the treatment of neuropathic corneal pain (NCP) and anterior segment eye diseases, with ordinary shares listed for trading on the Nasdaq Capital Market. OKYO plans to initiate a global Phase 3 pivotal clinical trial in the second half of this year, enrolling approximately 111 patients to evaluate a single-dose regimen of urcosimod for the treatment of NCP.
For further information, please visitwww.okyopharma.com.

OKYO Pharma LtdPaul SpencerBusiness Development and Investor Relations+44 (0) 207 495 2379Email:info@okyopharma.com

Frequently Asked Questions

Who is the Chief Development Officer of OKYO Pharma?

Gary S. Jacob, PhD, is the Chief Development Officer and Director of OKYO Pharma.

What recent action did Gary Jacob take regarding shares?

Gary Jacob purchased 3,500 ordinary shares at $1.40 each, increasing his holdings.

What is the focus of OKYO Pharma's clinical development?

OKYO Pharma is developing therapies for neuropathic corneal pain and eye diseases.

When will OKYO Pharma's Phase 3 trial begin?

The Phase 3 pivotal clinical trial is expected to start in the second half of this year.

ShareAdd on Google
Tags: OKYO Gary Jacob Phase 3 trial neuropathic corneal pain biopharmaceutical
Last updated: Jul 22, 2026

Biotech snapshot

Lead asset
Urcosimod is a preservative-free product; supplied in unit dose ampoules; administered QID for 12-weeksPhase 3
Neuropathic Corneal Pain →

Catalyst track record

+14%
best trade around OKYO's most recent catalyst

Peak hindsight return over a 120-day window, across 4 tracked FDA/PDUFA catalysts for OKYO.

See every catalyst's timing & PoA →